Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR
Journal of Biological Chemistry · 2024-02 · 300 (2) · 105650
DOI: 10.1016/j.jbc.2024.105650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024-02. Verfasst von Alok K Sharma und 15 weiteren Autor:innen. Beteiligte Einrichtung: NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), ras Proteins. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, U.S. Department of Energy, National Cancer Institute.
Abstract (Originalsprache)
Individual oncogenic KRAS mutants confer distinct differences in biochemical properties and signaling for reasons that are not well understood. KRAS activity is closely coupled to protein dynamics and is regulated through two interconverting conformations: state 1 (inactive, effector binding deficient) and state 2 (active, effector binding enabled). Here, we use 31P NMR to delineate the differences in state 1 and state 2 populations present in WT and common KRAS oncogenic mutants (G12C, G12D, G12V, G13D, and Q61L) bound to its natural substrate GTP or a commonly used nonhydrolyzable analog GppNHp (guanosine-5'-[(β,γ)-imido] triphosphate). Our results show that GppNHp-bound proteins exhibit significant state 1 population, whereas GTP-bound KRAS is primarily (90% or more) in state 2 conformation. This observation suggests that the predominance of state 1 shown here and in other studies is related to GppNHp and is most likely nonexistent in cells. We characterize the impact of this differential conformational equilibrium of oncogenic KRAS on RAF1 kinase effector RAS-binding domain and intrinsic hydrolysis. Through a KRAS G12C drug discovery, we have identified a novel small-molecule inhibitor, BBO-8956, which is effective against both GDP- and GTP-bound KRAS G12C. We show that binding of this inhibitor significantly perturbs state 1-state 2 equilibrium and induces an inactive state 1 conformation in GTP-bound KRAS G12C. In the presence of BBO-8956, RAF1-RAS-binding domain is unable to induce a signaling competent state 2 conformation within the ternary complex, demonstrating the mechanism of action for this novel and active-conformation inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland, USA. Electronic address: alok.sharma@nih.gov.
- Physical and Life Sciences (PLS) Directorate, Lawrence Livermore National Laboratory, Livermore, California, USA.
- NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland, USA.
- BridgeBio Oncology Therapeutics, BridgeBio Pharma, Inc, Palo Alto, California, USA.
- NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland, USA; BridgeBio Oncology Therapeutics, BridgeBio Pharma, In…
- NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc, Frederick, Maryland, USA. Electronic address: anna.maciag@nih.gov.
Förderung
- National Institutes of Health
- U.S. Department of Energy
- National Cancer Institute
- Frederick National Laboratory for Cancer Research
Zitieren
APA
Sharma, A. K., Pei, J., Yang, Y., Dyba, M., Smith, B., Rabara, D., Larsen, E. K., Lightstone, F. C., Esposito, D., Stephen, A. G., Wang, B., Beltran, P. J., Wallace, E., Nissley, D. V., McCormick, F., & Maciag, A. E. (2024). Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR. Journal of Biological Chemistry, 300(2), 105650. https://doi.org/10.1016/j.jbc.2024.105650
Vancouver
Sharma AK, Pei J, Yang Y, Dyba M, Smith B, Rabara D, et al. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR. Journal of Biological Chemistry. 2024;300(2):105650. doi:10.1016/j.jbc.2024.105650
BibTeX
@article{Sharma2024,
author = {Sharma, Alok K and Pei, Jun and Yang, Yue and Dyba, Marcin and Smith, Brian and Rabara, Dana and Larsen, Erik K and Lightstone, Felice C and Esposito, Dominic and Stephen, Andrew G and Wang, Bin and Beltran, Pedro J and Wallace, Eli and Nissley, Dwight V and McCormick, Frank and Maciag, Anna E},
title = {Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR},
journal = {Journal of Biological Chemistry},
year = {2024},
volume = {300},
number = {2},
pages = {105650},
doi = {10.1016/j.jbc.2024.105650}
}
EUVIMED